Insight

Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma

Amrita Krishnan

Nov 12, 2024, 17:56

Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a recent article by Amrita Krishnan on X:

“SWOG Cancer Research Network S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (mmMRD) to direct Therapy Duration (DRAMMATIC) by Dr. Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski.”

Multiple Myeloma

Title: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapying Patients with Multiple Myeloma (mm) Using Minimal Residual Disease To direct Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski

Multiple Myeloma

More posts featuring Mike Thompson.

Amrita Krishnan Antje Hoering cancer DRAMMATIC Mike Thompson multiple myeloma OncoDaily Oncology Parameswaran Hari Rachael Sexton Robert Z. Orlowski SWOG Cancer Research Network

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer